COMP and triple-A syndrome: Thus, therapeutic application of EGF2 peptidomimetic or compound derived from interaction motifs between AT1 and COMP to selectively inhibit AT1-β-arrestin-2 signaling in AAA may require additional concerns of the potential detrimental effects in other tissues or organs, such as heart.